Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687661 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL9908644 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL4013896 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL31589135 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL19463682 | 0.89 | SLC6A11 (0.43) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL20414094 | 0.88 | SLC6A11 (0.43) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL6855480 | 0.83 | CHRNB4 (0.34) | SLC6A1ALK | |
| Hydroxyamine SCHEMBL8631065 | 0.81 | SLC6A2 (0.33) | ALK | |
| SCHEMBL6855484 | 0.81 | SLC6A2 (0.32) | ALK | |
| Hydroxyamine SCHEMBL8631067 | 0.79 | SLC6A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ARGORNA PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293701-A1 | LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF | ASGR1, HAVCR2, SLC10A1 | SLC6A11 803/4885SLC6A1 554/4885TYMP 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.